Lynch syndrome
FDA Grants Marketing Authorization for Invitae Hereditary Cancer DNA Sequencing Test
The Invitae Common Hereditary Cancers Panel is the first test of its kind to obtain FDA marketing authorization, creating an easier pathway for similar tests.
UK National Health Service Rolls out Lynch Syndrome Genetic Testing
The new service will not only help guide patient treatment but also identify relatives who might be at higher risk of developing certain cancers.
Leica Biosystems Nabs 510(k) Clearance for Lynch Syndrome Test
The Danaher subsidiary's Bond MMR Antibody Panel provides IHC mismatch repair protein status, helping to identify potential Lynch syndrome among colorectal cancer patients.
Biocartis Nabs FDA 510(k) Clearance for Lynch Syndrome Screening Assay
The Idylla MSI Test identifies microsatellite instability in colorectal cancer tumors to aid in the identification of potential Lynch syndrome.
The firm's test for Lynch Syndrome determines the presence of variants in the DNA mismatch repair pathway.